Search Results - "Adriana Carlomagno"

Prednisone and long-term damage in systemic lupus erythematosus: Which is the threshold dose? A pilot study by Danza, Alvaro, Graña, Diego, Soto, Evelyn, Silveira, Gonzalo, Carlomagno, Adriana, Rebella, Martín

“…Objectives We aimed to study the daily dose of glucocorticoids in the first month associated with damage after 5 years of systemic lupus erythematosus (SLE)…”
Get full text

Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues by Porta, Sabrina, Danza, Alvaro, Arias Saavedra, Maira, Carlomagno, Adriana, Goizueta, María Cecilia, Vivero, Florencia, Ruiz-Irastorza, Guillermo

“…Since the discovery of glucocorticoids (GCs), their important anti-inflammatory effect, rapid mechanism of action, low cost, and accessibility have made them…”
Get full text

The Clinician Faced With Anticochlear Antibodies: What to Do With Them? by Carlomagno, Adriana, Silveira, Gonzalo, Rebella, Martín, Vola, Magdalena, Danza, Alvaro

“…BACKGROUNDAutoimmune inner ear disease as a cause of sensorineural hearing loss is a poorly understood entity. Thus, the role of anticochlear antibodies…”
Get full text

A novel form of Deleted in breast cancer 1 (DBC1) lacking the N-terminal domain does not bind SIRT1 and is dynamically regulated in vivo by Santos, Leonardo, Colman, Laura, Contreras, Paola, Chini, Claudia C., Carlomagno, Adriana, Leyva, Alejandro, Bresque, Mariana, Marmisolle, Inés, Quijano, Celia, Durán, Rosario, Irigoín, Florencia, Prieto-Echagüe, Victoria, Vendelbo, Mikkel H., Sotelo-Silveira, José R., Chini, Eduardo N., Badano, Jose L., Calliari, Aldo J., Escande, Carlos

“…The protein Deleted in Breast Cancer-1 is a regulator of several transcription factors and epigenetic regulators, including HDAC3, Rev-erb-alpha, PARP1 and…”
Get full text

Nefritis lúpica by Adriana Carlomagno, Gonzalo Silveira, Álvaro Danza, Ana Carina Pizzarossa, Martín Yandián, Federico Yandián, Martín Rebella

“…Introducción: las recomendaciones actuales del tratamiento de la nefritis lúpica (NL) apuntan a dosis de glucocorticoides más bajas para lograr el control de…”
Get full text

Se pueden disminuir las dosis de hidroxicloroquina en pacientes con lupus en remisión prolongada? by Adriana Carlomagno, Gonzalo Silveira, Martín Rebella, José Mario Sabio, Álvaro Danza

“…Carta al editor…”
Get full text

Estudio de una cohorte de pacientes con enfermedad tromboembólica venosa en seguimiento ambulatorio by Andrés, Facundo De, Ventura, Verónica, Silveira, Gonzalo, Carlomagno, Adriana, Baccelli, Augusto, López, Ignacio, Grille, Sofía, Roca, Federico

“…Resumen: La enfermedad tromboembólica venosa (ETEV) es una patología con morbilidad y mortalidad elevadas. Su manejo diagnóstico y terapéutico está en…”
Get full text

Evaluación de la prescripción de trombo-profilaxis farmacológica y valoración del impacto que generan distintas estrategias para mejorar su indicación by Silveira, Gonzalo, López, Ignacio, Carlomagno, Adriana, Andrés, Facundo De, Ventura, Verónica, Baccelli, Augusto, Grille, Sofía, Roca, Federico

“…Resumen: Introducción: La enfermedad tromboembólica venosa (ETEV) constituye la principal causa de muerte prevenible en pacientes hospitalizados. Actualmente…”
Get full text